MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- AMAR REMEDIES - MARICO
AMAR REMEDIES vs MARICO - Comparison Results
Current Valuations
| AMAR REMEDIES | MARICO | AMAR REMEDIES/ MARICO |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | -0.5 | 41.2 | - | View Chart |
| P/BV | x | 0.1 | 19.0 | 0.3% | View Chart |
| Dividend Yield | % | 0.0 | 1.1 | - |
Financials
 AMAR REMEDIES  MARICO |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AMAR REMEDIES Jun-12 |
MARICO Mar-18 |
AMAR REMEDIES/ MARICO |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 164 | 348 | 47.2% | |
| Low | Rs | 86 | 284 | 30.3% | |
| Sales per share (Unadj.) | Rs | 261.6 | 49.0 | 534.2% | |
| Earnings per share (Unadj.) | Rs | 17.4 | 6.4 | 271.3% | |
| Cash flow per share (Unadj.) | Rs | 22.3 | 7.1 | 313.9% | |
| Dividends per share (Unadj.) | Rs | 0 | 4.25 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 1.3 | 0.0% | |
| Book value per share (Unadj.) | Rs | 100.7 | 20.0 | 504.7% | |
| Shares outstanding (eoy) | m | 26.16 | 1,290.90 | 2.0% | |
| Bonus/Rights/Conversions | - | ESOP | - | ||
| Price / Sales ratio | x | 0.5 | 6.5 | 7.4% | |
| Avg P/E ratio | x | 7.2 | 49.3 | 14.6% | |
| P/CF ratio (eoy) | x | 5.6 | 44.5 | 12.6% | |
| Price / Book Value ratio | x | 1.2 | 15.8 | 7.8% | |
| Dividend payout | % | 0 | 66.3 | 0.0% | |
| Avg Mkt Cap | Rs m | 3,270 | 407,860 | 0.8% | |
| No. of employees | `000 | NA | 1.7 | 0.0% | |
| Total wages/salary | Rs m | 163 | 4,222 | 3.9% | |
| Avg. sales/employee | Rs Th | NM | 37,971.1 | - | |
| Avg. wages/employee | Rs Th | NM | 2,535.9 | - | |
| Avg. net profit/employee | Rs Th | NM | 4,969.7 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 6,844 | 63,222 | 10.8% | |
| Other income | Rs m | 21 | 846 | 2.5% | |
| Total revenues | Rs m | 6,865 | 64,068 | 10.7% | |
| Gross profit | Rs m | 1,131 | 11,378 | 9.9% | |
| Depreciation | Rs m | 128 | 891 | 14.4% | |
| Interest | Rs m | 398 | 162 | 246.1% | |
| Profit before tax | Rs m | 626 | 11,171 | 5.6% | |
| Minority Interest | Rs m | 0 | -1 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -50 | 0 | - | |
| Tax | Rs m | 121 | 2,896 | 4.2% | |
| Profit after tax | Rs m | 455 | 8,275 | 5.5% | |
| Gross profit margin | % | 16.5 | 18.0 | 91.8% | |
| Effective tax rate | % | 19.3 | 25.9 | 74.6% | |
| Net profit margin | % | 6.6 | 13.1 | 50.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 4,904 | 27,934 | 17.6% | |
| Current liabilities | Rs m | 3,581 | 14,576 | 24.6% | |
| Net working cap to sales | % | 19.3 | 21.1 | 91.5% | |
| Current ratio | x | 1.4 | 1.9 | 71.5% | |
| Inventory Days | Days | 124 | 87 | 142.5% | |
| Debtors Days | Days | 100 | 20 | 509.4% | |
| Net fixed assets | Rs m | 1,689 | 5,909 | 28.6% | |
| Share capital | Rs m | 262 | 1,291 | 20.3% | |
| "Free" reserves | Rs m | 2,358 | 24,474 | 9.6% | |
| Net worth | Rs m | 2,635 | 25,765 | 10.2% | |
| Long term debt | Rs m | 507 | 198 | 255.7% | |
| Total assets | Rs m | 6,862 | 40,815 | 16.8% | |
| Interest coverage | x | 2.6 | 70.1 | 3.7% | |
| Debt to equity ratio | x | 0.2 | 0 | 2,500.0% | |
| Sales to assets ratio | x | 1.0 | 1.5 | 64.4% | |
| Return on assets | % | 12.4 | 20.7 | 60.1% | |
| Return on equity | % | 17.3 | 32.1 | 53.8% | |
| Return on capital | % | 31.0 | 43.6 | 71.0% | |
| Exports to sales | % | 4.0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | 273 | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 273 | 3,249 | 8.4% | |
| Fx outflow | Rs m | 2 | 2,087 | 0.1% | |
| Net fx | Rs m | 271 | 1,161 | 23.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | -313 | 5,545 | -5.6% | |
| From Investments | Rs m | -489 | 169 | -289.6% | |
| From Financial Activity | Rs m | 769 | -5,675 | -13.5% | |
| Net Cashflow | Rs m | -33 | 79 | -41.1% | |
Share Holding
| Indian Promoters | % | 25.5 | 59.6 | 42.8% | |
| Foreign collaborators | % | 0.0 | 0.1 | - | |
| Indian inst/Mut Fund | % | 9.2 | 2.6 | 353.8% | |
| FIIs | % | 0.0 | 31.0 | - | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 65.3 | 6.7 | 974.6% | |
| Shareholders | 13,061 | 37,128 | 35.2% | ||
| Pledged promoter(s) holding | % | 99.7 | 0.0 | - |
Compare AMAR REMEDIES With: K.S.OILS LTD BATA INDIA HUL KARUTURI GLOBAL GODREJ INDUSTRIES
Compare AMAR REMEDIES With: UNILEVER PLC. (UK) P&G (US) HYPERMARCAS (Brazil)
|
| |
Today's Market
Sensex Jumps 1,921 Points, FM's Tax Relief, and Top Cues in Focus Today(Pre-Open)
Share markets in India jumped sharply on Friday after Finance Minister Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.
Related Views on News
MARICO Announces Quarterly Results (1QFY20); Net Profit Up 21.1% (Quarterly Result Update)
Aug 5, 2019 | Updated on Aug 5, 2019For the quarter ended June 2019, MARICO has posted a net profit of Rs 3 bn (up 21.1% YoY). Sales on the other hand came in at Rs 22 bn (up 6.9% YoY). Read on for a complete analysis of MARICO's quarterly results.
MARICO Announces Quarterly Results (4QFY19); Net Profit Up 122.4% (Quarterly Result Update)
May 7, 2019 | Updated on May 7, 2019For the quarter ended March 2019, MARICO has posted a net profit of Rs 4 bn (up 122.4% YoY). Sales on the other hand came in at Rs 16 bn (up 8.7% YoY). Read on for a complete analysis of MARICO's quarterly results.
MARICO LTD Announces Quarterly Results (3QFY19); Net Profit Up 12.7% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, MARICO LTD has posted a net profit of Rs 3 bn (up 12.7% YoY). Sales on the other hand came in at Rs 19 bn (up 14.6% YoY). Read on for a complete analysis of MARICO LTD's quarterly results.
MARICO LTD Announces Quarterly Results (2QFY19); Net Profit Up 17.6% (Quarterly Result Update)
Nov 5, 2018 | Updated on Nov 5, 2018For the quarter ended September 2018, MARICO LTD has posted a net profit of Rs 2 bn (up 17.6% YoY). Sales on the other hand came in at Rs 18 bn (up 19.6% YoY). Read on for a complete analysis of MARICO LTD's quarterly results.
MARICO LTD Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)
Aug 6, 2018 | Updated on Aug 6, 2018For the quarter ended June 2018, MARICO LTD has posted a net profit of Rs 3 bn (up 10.3% YoY). Sales on the other hand came in at Rs 20 bn (up 19.8% YoY). Read on for a complete analysis of MARICO LTD's quarterly results.
More Views on NewsMost Popular
Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)
Sep 12, 2019News headlines predict gloom and doom for India these days. You should ignore them.
A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)
Sep 16, 2019The stock market today is throwing up a great opportunity to pile on quality stocks.
A Recession Proof Stock You Can Bet On(Profit Hunter)
Sep 10, 2019Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.
My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)
Sep 19, 2019The India we knew is changing. Here's how you can benefit from this change.
Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)
Sep 20, 2019Are investors overdoing their euphoria post the corporate tax cut bonanza?
MoreAMAR REMEDIES SHARE PRICE
Dec 11, 2013 (Close)
TRACK AMAR REMEDIES
- Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AMAR REMEDIES
AMAR REMEDIES - COLGATE COMPARISON
COMPARE AMAR REMEDIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.